



PRESS RELEASE

CARMAT to present at the 64th congress of the French Society for Thoracic and Cardiovascular Surgery in Lyon

Presentation of study results on anatomic compatibility of patients eligible for CARMAT artificial heart implantation

Paris, May 25th 2011

CARMAT SA (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, today announced that results of a 100-patient study will be presented on 3-dimensional imaging as a virtual tool for anatomical compatibility assessment of its artificial heart, at the 64th congress of the French Society for Thoracic and Cardiovascular Surgery, opening today in Lyon (France).

The presentation (poster C-42) is part of the sessions on May 26th and 27th and is titled "*3D image processing as a virtual fitting tool for the selection of patients requiring an artificial heart*".

The study focused on a unique service that will be provided to hospitals implanting the CARMAT heart: a 3D simulation, generated from the patient's own imaging data that assesses anatomic compatibility of the device before implantation. The poster will be presented by Antoine Capel, Clinical Department manager at CARMAT.

The study showed that 65% of the 100 patients studied were anatomically compatible (86% for men and 14% for women).

"Since the prevalence of the target indication is 50% higher in men than in women, these results support the device's market perspectives", concludes Marcello Conviti, CEO of CARMAT.

About CARMAT: CARMAT, the world's most advanced total artificial heart project.

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsas.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Carmat ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French *Autorité des marchés financiers* ("AMF") granted its visa number 10-180 on June 14, 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.



CARMAT

Marcello Conviti

CEO

Patrick Coulombier

COO

Valérie Leroy

Director, Marketing and Investor Relations

tel.: +33 139 456450

mobile/cellular: +33 609 080347

investors@carmatsas.com

NewCap.

Financial Communication & Investor relations

Axelle Vuillermet / Emmanuel Huynh

Tel.: 01 44 71 94 94

carmat@newcap.fr



Name: **CARMAT**

ISIN code: **FR0010907956**

Ticker: **ALCAR**